Empowered Funds LLC Takes $909,000 Position in Lantheus Holdings, Inc. $LNTH

Key Points

• Empowered Funds LLC initiated a roughly $909,000 position in Lantheus Holdings during the first quarter by purchasing 11,979 shares. Institutional investors and hedge funds collectively own 99.06% of the company.
• Lantheus reported quarterly earnings of $1.55 per share, exceeding estimates of $1.30, while revenue rose 2.7% year over year to $388.18 million.
• Analyst sentiment is mixed: five analysts rate the stock Buy and nine rate it Hold, producing an overall “Hold” rating and an average price target of $108.11.

Empowered Funds LLC bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 11,979 shares of the medical equipment provider's stock, valued at approximately $909,000.

Other institutional investors have also added to or reduced their stakes in the company. Carmignac Gestion boosted its position in Lantheus by 18.4% in the first quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider's stock worth $100,729,000 after purchasing an additional 206,000 shares during the last quarter. Defilade Capital Management L.P. purchased a new stake in Lantheus in the first quarter worth $18,917,000. Parallel Advisors LLC raised its stake in shares of Lantheus by 95.9% in the first quarter. Parallel Advisors LLC now owns 1,060 shares of the medical equipment provider's stock valued at $80,000 after buying an additional 519 shares during the period. Allen Capital Group LLC purchased a new position in shares of Lantheus during the 1st quarter valued at $250,000. Finally, Western Wealth Management LLC bought a new stake in Lantheus in the 1st quarter valued at about $25,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Performance

Shares of Lantheus stock opened at $100.95 on Monday. The company's 50-day moving average price is $104.23 and its 200-day moving average price is $89.34. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. Lantheus Holdings, Inc. has a 12-month low of $49.67 and a 12-month high of $111.86. The company has a market cap of $6.59 billion, a price-to-earnings ratio of 24.38 and a beta of -0.03.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating the consensus estimate of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The company had revenue of $388.18 million during the quarter, compared to analysts' expectations of $363.23 million. During the same quarter in the previous year, the company earned $1.57 earnings per share. Lantheus's revenue for the quarter was up 2.7% on a year-over-year basis. On average, equities analysts expect that Lantheus Holdings, Inc. will post 4.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on LNTH shares. B. Riley Financial reiterated a "buy" rating on shares of Lantheus in a research report on Wednesday, July 29th. William Blair set a $102.50 price target on shares of Lantheus in a research note on Monday, August 3rd. Truist Financial downgraded shares of Lantheus from a "buy" rating to a "hold" rating and cut their price objective for the stock from $125.00 to $102.50 in a report on Monday, August 3rd. Wall Street Zen lowered shares of Lantheus from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 9th. Finally, Weiss Ratings cut shares of Lantheus from a "hold (c+)" rating to a "hold (c)" rating in a report on Thursday. Five investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $108.11.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source